Bevacizumab for Newly Diagnosed Ovarian Cancers: Best Candidates Among High-Risk Disease Patients (ICON-7)

Bevacizumab is approved as a maintenance treatment in first-line setting in advanced-stage III-IV ovarian cancers, because GOG-0218 and ICON-7 phase III trials demonstrated progression-free survival benefits. However, only the subgroup of patients with high-risk diseases (stage IV, and incompletely...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:JNCI Cancer Spectr
Main Authors: Colomban, Olivier, Tod, Michel, Peron, Julien, Perren, Timothy J, Leary, Alexandra, Cook, Adrian D, Sajous, Christophe, Freyer, Gilles, You, Benoit
Formato: Artigo
Idioma:Inglês
Publicado em: Oxford University Press 2020
Assuntos:
Brief Communication
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7306189/
https://ncbi.nlm.nih.gov/pubmed/32596636
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/jncics/pkaa026
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados